Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

179.89 +3.71 (+2.11%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

57 58 Next >

Can These 2 Stocks Crush the Market Again in 2023? ↗

December 04, 2022

Both are riding the wave of major clinical wins

Via The Motley Fool

Is Biogen Stock a Buy Now? ↗

December 04, 2022

Its revenue now has a plausible path to doubling, but risks remain high.

Via The Motley Fool

Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗

December 02, 2022

The S&P 500 is fighting for its 200-day, a critical level for the uptrend.

Via Investor's Business Daily

Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate ↗

November 30, 2022

Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).

Via Benzinga

CrowdStrike (CRWD) Stock Sinks on Weak Guidance ↗

November 30, 2022

CrowdStrike (CRWD) stock is falling on Wednesday following the release of its earnings report for the third quarter of 2022.

Via InvestorPlace

26 Analysts Have This to Say About Biogen ↗

November 30, 2022

Via Benzinga

BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen ↗

November 30, 2022

Biogen (BIIB) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate.

Via InvestorPlace

Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's ↗

November 30, 2022

Via Benzinga

Biogen Stock Is Surging Today: What's Going On? ↗

November 30, 2022

Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's

Via Benzinga

Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday ↗

November 30, 2022

Mizuho cut Alphabet Inc. (NASDAQ: GOOGL) price target from $140 to $135. Mizuho analyst James Lee maintained a Buy rating on the stock. Alphabet shares gained 0.4% to $95.53 in pre-market trading.

Via Benzinga

Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors ↗

November 29, 2022

The update from Eisai suggests there is a benefit question ahead of the companies.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

November 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success ↗

November 28, 2022

Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies.

Via Investor's Business Daily

Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall ↗

November 28, 2022

A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that...

Via Benzinga

Market Currents: Why Pick Stocks? ↗

November 28, 2022

Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...

Via Talk Markets

2 Stocks Near 52-Week Highs That Could Climb Higher ↗

November 28, 2022

This pair of stocks are bucking the trend and they could climb even higher.

Via The Motley Fool

CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention

November 23, 2022

The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400.

Via TheNewswire.com

Topics ETFs Economy Stocks

CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention

November 23, 2022

By Jad Malaeb, Benzinga

Via News Direct

Topics ETFs Economy

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

CBOE's Weekly Market Recap: Nov.14-18 – Biogen's Alzheimer's Drug Captures Investors' Attention ↗

November 23, 2022

The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400.

Via Benzinga

Not All Offices Are Created Equal… You Can Profit From One Sector That’s Poised to See Demand Growth ↗

November 22, 2022

Despite what we might see in the upcoming year with office real estate or specific companies within the life sciences industry, REITs with exposure to in-demand properties remain a great way to earn...

Via Talk Markets

TEVA Stock Alert: What to Know About Teva Pharmaceuticals’ New CEO ↗

November 21, 2022

Teva Pharmaceuticals (TEVA) stock is sliding on Monday after the company announced Richard Francis as its newest president and CEO.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

November 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

3 Stocks to Avoid Right Now ↗

November 17, 2022

Even though many stocks have fallen sharply in price, not all are bargains -- investors must remains selective.

Via The Motley Fool

CONTINUED INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Continues to Investigate Biogen Inc.’s Directors and Officers for Breach of Fiduciary Duties – BIIB

November 17, 2022

From Scott+Scott Attorneys at Law LLP

Via Business Wire

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗

November 15, 2022

Via Benzinga

Why Is Cassava Sciences (SAVA) Stock Up Today? ↗

November 14, 2022

Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.

Via InvestorPlace

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗

November 14, 2022

Via Benzinga

Why Is AST SpaceMobile (ASTS) Moving Today? ↗

November 14, 2022

AST SpaceMobile (ASTS) stock is a hot topic on Monday as investors react to the company setting up its BlueWalker 3 satellite array.

Via InvestorPlace

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.